The Phase 3 trial for Genting's Alzheimer’s drug, conducted by their associate company TauRx, is now completed, and the drug is awaiting regulatory approval. TauRx is working with authorities in both the United States and the United Kingdom to clear the drug, which is known as hydromethylthionine mesylate (HMTM). This drug, designed to slow cognitive decline in Alzheimer's patients, has demonstrated favorable safety profiles and cost advantages, as it is orally administered compared to many competitors that require intravenous delivery.

Currently, TauRx has a manufacturing facility on standby, prepared to begin production as soon as approval is granted. This readiness emphasizes the company's focus on quickly bringing the drug to market once regulatory clearance is obtained, which could provide Genting with significant returns if the approval process is successful.

The manufacturer ready to produce TauRx’s Alzheimer's drug, hydromethylthionine mesylate (HMTM), after regulatory approval appears to be part of TauRx’s own advanced preparation efforts, though specific details about a third-party manufacturer are not fully disclosed. TauRx has filed for regulatory approval in the UK and is planning to release HMTM for mild to moderate Alzheimer’s stages, with expectations for rapid production and market entry upon approval.

The drug targets tau protein buildup and aims to slow disease progression, which TauRx claims will be a breakthrough if approved. As the regulatory review progresses, TauRx is likely managing its production through its in-house or partnered facilities, though further information about the exact manufacturing partner may be released once approvals are secured.

TauRx的阿尔茨海默症药物——甲基硫氢氯甲烷 (HMTM) 的生产已经进入准备阶段，一旦获得监管批准即可投入生产。目前，TauRx已向英国监管机构提交审批申请，计划针对轻度至中度阿尔茨海默症患者上市此药物，并期待获批后快速投放市场。

HMTM旨在减少大脑中tau蛋白的累积，从而延缓疾病进展。若获批准，该药物将成为该病领域的一项突破。TauRx已在内部进行生产准备，或通过合作的设施来保证生产。不过，有关具体生产合作方的进一步信息可能会在获得监管批准后公布。

TauRx公司（Genting的关联公司）已经完成其用于阿尔茨海默症的药物甲基硫氢氯甲烷 (HMTM) 的第三阶段临床试验，现正等待监管批准。TauRx正与美国和英国的监管机构合作，以推进该药物的审批。HMTM 旨在减缓阿尔茨海默症患者的认知衰退，并具有较好的安全性和成本优势，尤其因其为口服形式，不同于许多需要静脉注射的竞品药物。

目前，TauRx已经备有生产设施，一旦获得批准便可立即投产。这种准备突显了公司在获得监管批准后迅速将该药物推向市场的决心。如果审批成功，Genting预计将从中获得显著的收益回报。

其实
这是 胆量 和 智慧 的 对决

在股市里
要等到好消息才买进的
99％ 是散户

当然
在股市里
风险越高 回报率也高

不要一天到晚看这种垃圾新闻

Gens 都有2.7亿马币。。。
Gent特有52％
Genm 至少150m-200m
Genp 还有其他。。。自己算算看。。
股息还不给？？

为什么一直叫我,明天没市想静静的,吹水留言也又没钱赚,手机没这个apps,要用iPad 啦哈哈哈哈哈…………. 定点来,肥佬戴了头盔在大厅哈哈哈哈哈…………今天买了392………前面第一次397出405,第二次也是买397出405,第三次再买397,跌到392再买……392的出400,397出403,四块以下操作了四次…….. 今天工作忙那392忘了拉岀来结果中了,383我会再买入哈哈哈………. 我讲了等下大家又喷我,又不让我找静静哈哈………四块以上我也操作了几次,我已经说过了,现在手上还有很多票本钱应该已低过四块的,得空才算一下啦哈哈哈哈哈…….. 我现在在新加坡了,原本要回K L的,结果大客户载我过新加坡在金沙住两晚,金沙对我们这两位vvip 是超大方的哈哈哈哈哈……….. 闪人了祝大家有个愉快的周末…………